SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.
Details of the company's participation are as follows:
Interested parties may access the live webcast of the fireside chat by visiting the Investors section of the Atossa website at https://investors.atossatherapeutics.com. The webcast replay will be archived on the Atossa website for 90 days following the conclusion of the event.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com.
Contact:
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.20 |
| Daily Change: | -0.08 -6.25 |
| Daily Volume: | 1,320,567 |
| Market Cap: | US$150.910M |
November 20, 2024 November 12, 2024 November 05, 2024 November 04, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
